Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 989 across all filing types
Latest filing 2021-08-10 Call Transcript
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
Telix H1 2021 Results and Company Update Conference Call 1
Call Transcript Classification · 90% confidence The document is an announcement of an upcoming investor conference call to present the company's H1 2021 financial results and operational update. It includes details about the call date, registration link, company background, and investor relations contact information. There are no actual financial statements or detailed financial analysis included in the text. The document is short (2439 characters) and serves as a notice for the call rather than the call transcript itself. Therefore, it is not the full Call Transcript (CT) but rather an announcement related to it. Given the options, the best fit is Call Transcript (CT) because the document is about a conference call presenting financial results, and no other category fits better. Confidence is high as the document clearly states it is about a conference call for H1 2021 results.
2021-08-10 English
1st Patient Dosed in CUPID study of TLX592 3 pages 227.2KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing the dosing of the first patient in a clinical trial (CUPID study) for a new prostate cancer therapy candidate by Telix Pharmaceuticals. It provides detailed information about the study, the drug candidate, and the company's background. There are no financial statements, regulatory filings, or formal report structures such as annual or interim reports. The content focuses on clinical trial progress and company product development rather than financial or governance matters. This type of document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit into other specific categories like financial reports, management changes, or capital updates.
2021-08-04 English
Telix Seneffe Production Facility - Progress Update 2 pages 202.8KB
Regulatory Filings Classification · 95% confidence The document is a progress update announcement regarding the decommissioning authorization of a cyclotron at Telix Pharmaceuticals' production facility in Belgium. It includes operational and regulatory information about the facility and company background but does not contain financial data, earnings, or detailed report content. The document is relatively short (4409 characters) and serves as a corporate update rather than a formal financial or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings that require substantive financial or regulatory content. It is an operational progress update announcement, which aligns best with a general Regulatory Filings (RNS) category as a fallback for miscellaneous corporate announcements that do not fit other specific categories.
2021-07-29 English
Notification regarding unquoted securities - TLX 7 pages 30.8KB
Share Issue/Capital Change Classification · 100% confidence The document is a detailed notification regarding the issue of unquoted equity securities, specifically options issued under an employee incentive scheme by Telix Pharmaceuticals Limited. It includes specifics such as the number of securities issued, exercise price, expiry date, and compliance with ASX listing rules. The content focuses on the issuance of new securities and related details rather than financial results, management changes, or other report types. This matches the definition of a Share Issue/Capital Change announcement, which covers new share issues or other capital changes. The document length is sufficient and contains substantive details about the securities issued, confirming it is not merely an announcement of a report or a regulatory filing. Therefore, the appropriate classification is Share Issue/Capital Change (SHA).
2021-07-21 English
Notification regarding unquoted securities - TLX 7 pages 30.8KB
Share Issue/Capital Change Classification · 100% confidence The document is a detailed notification about the issue of unquoted equity securities by Telix Pharmaceuticals Limited. It includes specifics such as the number of securities issued, their type (share rights with nil exercise price), expiry dates, and references to the company's equity incentive plan. The document is structured as a formal announcement to the ASX (Australian Securities Exchange) regarding the issuance of new securities under an employee incentive scheme. It does not contain financial statements, earnings data, or management discussion, nor is it a report or presentation. It is clearly an announcement about a capital change related to securities issuance. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length and detail support a high confidence in this classification.
2021-07-21 English
Notification of cessation of securities - TLX 4 pages 24.5KB
Regulatory Filings Classification · 95% confidence The document is a notification about the cessation of securities, specifically options that have lapsed due to conditions not being met. It provides details about the securities that have ceased, the reasons for cessation, and the updated issued capital following these changes. The document is an announcement related to changes in the company's securities, not a full financial report or detailed analysis. It fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement about securities status changes and does not contain financial statements or detailed financial data.
2021-07-21 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.